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ABSTRACT
The active metabolite of irinotecan (CPT-11), 7-ethyl-
10-hydroxycamptothecin (SN-38), is either formed through
enzymatic cleavage of CPT-11 by carboxyl esterases (CEs)
or through cytochrome P-450 3A-mediated oxidation to
7-ethyl-10-[4-(1-piperidino)-1-amino] carbonyloxycampto-
thecin (NPC) and a subsequent conversion by CE. In the
liver, SN-38 is glucuronidated (SN-38G) by UGT1A1, which
also conjugates bilirubin. Fourteen patients were treated
with 350 mg/m2 CPT-11, and we performed pharmacoki-
netic analysis during a 500-h collection period. The half-life
and area under the plasma concentration-time curve of
SN-38 were 47 6 7.9 h and 2.0 6 0.79 mMzh, respectively,
both representing a 2-fold increase as compared with earlier
reported estimates (A. Sparreboom et al., Clin. Cancer Res.,
4: 2747–2754, 1998). As an explanation for this phenome-
non, we noted substantial formation of SN-38 from CPT-11
and NPC by plasma CE, consistent with the low circulating
levels of NPC observed. In addition, transport studies in
Caco-2 monolayers indicated that nonglucuronidated SN-38
could cross the membrane from apical to basolateral, indi-
cating the potential for recirculation processes that can
prolong circulation times. Interestingly, individual levels of
fecal b-glucuronidase, which is known to mediate SN-38G
hydrolysis, were not related to any of the SN-38 kinetic
parameters (r 5 0.09; P 5 0.26), suggesting that interindi-
vidual variation in this enzyme is unimportant in explaining
SN-38 pharmacokinetic variability. We have also found, in
contrast to earlier data, that SN-38G/SN-38 plasma concen-
tration ratios decrease over time from ;7 (up to 50 h) to ;1
(at 500 h). This decrease could be explained by the fact that
glucuronidation of SN-38 and bilirubin is increasingly com-
petitive at lower drug levels. In addition, no evidence was
found for SN-38G transport through the Caco-2 cells. Our
findings indicate that until now the circulation time of SN-38
has been underestimated. This is of crucial importance to
our understanding of the clinical action of CPT-11 and for
future pharmacokinetic/pharmacodynamic relationships.
INTRODUCTION
CPT-11,3 a water-soluble derivative of camptothecin, is
currently registered for use in patients with metastatic colorectal
cancer refractory to 5-fluorouracil therapy as well as first-line
therapy and has shown clinical activity against several other
types of solid tumors (1, 2). CPT-11 itself has weak, if any,
pharmacological activity in vitro and is thought to exert its
antitumor activity in vivo after enzymatic cleavage by a CE that
generates the active metabolite, SN-38, which is at least 100-
fold more cytotoxic than CPT-11 (3). Peripheral converting
enzyme activity in animals has been characterized in serum (4),
liver (5), and the small intestine (6), and preliminary evidence
indicates CE activity within the tumor as well (7–9). SN-38 can
be metabolized further very efficiently by UDP glucuronosyl-
transferase 1A1 (10) and 1A7 (11) to an inactive b-glucuronide
derivative, SN-38G (12, 13). Another metabolic pathway of
CPT-11 consists of a cytochrome P-450 3A4 and 3A5-mediated
oxidation of the bipiperidine side chain attached to the core
structure (14, 15). The main metabolites resulting from this
pathway have been identified as APC (16) and NPC (17).
Although APC has been shown to be a poor substrate of CE in
in vitro models (16), NPC can be converted into SN-38 by liver
CE and, as such, may contribute to the overall production of the
pharmacologically active species (17). We reported previously
that CPT-11 is predominantly eliminated in feces after hepato-
biliary and intestinal secretion, with unchanged drug as the
major excretion product followed by smaller amounts of SN-38
and APC (18). Interestingly, SN-38G concentrations in feces
were very low, presumably as a result of hydrolysis of the
glucuronic acid moiety by bacterial b-glucuronidases (18, 19).
We hypothesized, based also on the long terminal disposition
half-life and extensive biliary secretion, that CPT-11 and its
metabolites can undergo enterohepatic recirculation, and thatReceived 2/4/00; revised 4/4/00; accepted 4/7/00.
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this might play a role in the variability of pharmacokinetic
parameters observed earlier. In the present study, we have
reexamined the plasma disposition of CPT-11 and its metabo-
lites using an extended sampling time period of 500 h in a group
of patients with colorectal cancer receiving the drug as single
agent at a dose level of 350 mg/m2 and performed various in
vitro experiments to explain the observed phenomena.
PATIENTS AND METHODS
Patients and Treatment. Patients with a histologically
or cytologically confirmed diagnosis of colorectal cancer refrac-
tory to standard therapy or for whom other treatment options
were not available were eligible for the present study. Addi-
tional eligibility criteria included: age between 18 and 70 years;
Eastern Cooperative Oncology Group performance status #1;
no previous treatment with antineoplastic agents for at least 4
weeks (or 6 weeks in case of nitrosoureas or mitomycin C); no
prior treatment with CPT-11 or other topoisomerase I inhibitors;
adequate hematopoietic (WBC count .3.0 3 109/liter, absolute
neutrophil count .2.0 3 109/liter, and platelet count .100 3
109/liter), renal (serum creatinine concentration #135 mM or
creatinine clearance $60 ml/min) and hepatic function (total
serum bilirubin #1.25 3 upper normal limit, and ASAT and
ALAT concentrations #3.0 3 upper normal limits); and no
unresolved bowel obstruction or chronic colic disease. The
current clinical protocol was approved by the Rotterdam Cancer
Institute Review Board, and all patients signed informed consent
before study entry.
Vials that contained 40 or 100 mg of CPT-11 (as a hydro-
chloride trihydrate form) formulated as a concentrated sterile
solution (active drug concentration, 20 mg/ml) in d-sorbitol and
a lactic acid-sodium hydroxide buffer system of pH 3.5–4.5
were provided by Rhoˆne-Poulenc Rorer (Antony Cedex,
France). The CPT-11 dose of 350 mg/m2 was administered as a
90-min i.v. infusion, after dilution of the pharmaceutical prep-
aration in 250 ml of isotonic sodium chloride. In all patients,
premedication consisted of 8 mg of ondansetron i.v. combined
with 10 mg of dexamethasone i.v., administered 30 min before
the start of chemotherapy.
Sample Collection and Handling. Blood samples for
pharmacokinetic analysis were drawn from a vein in the arm
opposite to that used for drug infusion and collected in 10-ml
glass tubes containing lithium heparin as anticoagulant. Samples
were obtained at the following time points: before drug admin-
istration; at 0.5, 1, and 1.5 h during infusion; and 0.17, 0.33, 0.5,
1, 1.5, 2, 4, 5, 8.5, 24, 32, 48, 56, 196, 360, and 504 h after the
end of infusion. Blood was immediately processed to plasma by
centrifugation for 5 min at 2500 rpm (4°C), which was then
stored at 280°C until the time of analysis (see below). A
pretreatment feces sample was collected from all patients 1 day
prior to drug administration in a polystyrene container and
stored immediately at 280°C. After thawing, these samples
were homogenized individually on ice (at 0°C) to prevent en-
zyme degradation in one or two volumes of a 0.1 M sodium
acetate buffer (pH 7.0), depending on the water content of the
sample, using an Ultra-Turrax T25 homogenizer (IKA-
Labortechnik, Dottingen, Germany). The homogenates were
centrifuged for 5 min at 15,000 rpm, and the clear supernatants
were diluted 1-fold with 50% glycerol in water (v/v). The
dilutions were stored at 280°C until analysis for b-glucuroni-
dase activity (see below).
Drug Analysis. Pure reference standards of CPT-11 hy-
drochloride trihydrate (batch, KO16), and the metabolites SN-
38G trifluoroacetate (batch, YEO265), NPC trifluoroacetate
(batch, YEO304), and SN-38 hydrochloride (batch, LIE783)
were kindly provided by Rhoˆne-Poulenc Rorer and were used as
received. Drug concentrations in plasma were determined as the
total of lactone and carboxylate forms by a validated HPLC
method with fluorescence detection as described previously
(20). This method was further modified, as reported, to allow
determinations of SN-38 and SN-38G at the low femtomol level
(21). Because of straying fluorescence characteristics, an incom-
plete extraction, and the compound’s low relative retention on
the reversed-phase HPLC column (Hypersil ODS with 5 mm
particles), the unchanged parent drug could not be detected with
this latter method (21). Likewise, attempts to separately measure
SN-38 lactone levels and lactone to total ratios of SN-38 with
similar sensitivity characteristics as described above for SN-38
total drug (21) have not yet been successful because of inter-
ference from endogenous plasma constituents.
Pharmacokinetic Analysis. Individual plasma concen-
trations of CPT-11 and its metabolites were fitted to a three-
compartment model using the Siphar version 4.0 software pack-
age (SIMED, Cre´teil, France), as described (18). The rate
constants of the various disposition phases and the AUC were
estimated with a weighted-least squares method (weighting fac-
tor, 1/y) using the fitted model, whereas the total plasma clear-
ance of CPT-11 was calculated by dividing dose (expressed in
mg base equivalents per squared meter of body surface area) and
the observed AUC. The Cmax values (peak drug level) were
determined graphically (as observed values) in a concentration-
time scatter plot. Metabolic ratios were calculated as defined
(22) and included the relative extent of conversion of CPT-11 to
SN-38 (i.e., AUCSN-38:AUCCPT-11) and the relative extent of
glucuronidation of SN-38 (i.e., AUCSN-38G:AUCSN-38). The lat-
ter was also evaluated as a function of time after drug admin-
istration. The systemic SN-38 glucuronidation rate in individual
patients was estimated by calculation of the biliary index values
(23), expressed as AUCCPT-11 3 (AUCSN-38:AUCSN-38G).
Measurement of Fecal b-Glucuronidase Activity. The
enzyme activity was determined by a miniaturized colorimetric
assay using phenolphthalein glucuronic acid as an artificial
substrate, based on a procedure described for b-glucuronidase in
bile of mini pigs (24). Briefly, 20-ml sample aliquots of feces
homogenate were mixed with 20 ml of 0.1 M sodium acetate
buffer (pH 7.0) containing 0.2% (w/v) BSA and 10 ml of the
same buffer in the presence of 0.03 M phenolphthalein glucu-
ronic acid (Sigma-Aldrich Co., Zwijndrecht, the Netherlands)
and incubated for 1 h at 37°C in a shaking water bath. The
enzymatic reaction was terminated by the addition of 200 ml of
0.1 M sodium phosphate buffer (pH 12.0), and the reaction
product phenolphthalein was determined by measurement of the
absorbance at 550 nm against a reagent blank on a Bio-Rad
Model 550 automated microplate reader (Bio-Rad Laboratories,
Hercules, CA). A calibration standard curve of phenolphthalein
was constructed on the day of analysis, and concentration versus
absorbance data were fitted by linear regression analysis. The
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mean regression equation had slope and y-intercept values of
0.292 6 0.021 and 20.004 6 0.013 (n 5 15), respectively, with
a Pearson’s moment correlation coefficient .0.9943. Enzyme
activity levels in unknown feces samples were calculated in
triplicate using interpolation of the corresponding regression
analysis and expressed as micrograms of phenolphthalein liber-
ated per h at 37°C per milligrams of feces based on dry-weight
measurements (mg/h/mg). A formal method validation was per-
formed as described (25) by replicate analysis of quality control
samples spiked to contain three different concentrations on
several occasions in the presence of a duplicate 7-point calibra-
tion curve and reference samples containing 1.6 units/h of
lyophilized type IX-A b-glucuronidase (EC 3.2.1.31) from
Escherichia coli (Sigma Chemical Co., St. Louis, MO) dis-
solved in 50% glycerol in 0.1 M sodium acetate buffer (v/v). The
within-run and between-run precision, as determined by one-
way ANOVA, ranged from 2.18 to 3.55% and 2.84 to 4.89%
(n 5 22 at each of the concentrations), respectively, with a mean
percentage deviation from nominal values of less than 66.14%
for phenolphthalein data and 63.30% for the b-glucuronidase
reference standard.
In Vitro Metabolism of CPT-11 and NPC. Biotransfor-
mation of CPT-11 and NPC into SN-38 was studied in freshly
prepared aliquots of human plasma, following a 5-min centrif-
ugation step at 3000 3 g of whole blood samples obtained from
healthy volunteers. Prior to incubation, plasma samples were
placed in a shaking water bath at 37°C for 5 min. Aliquots of 50
ml of the lactone forms of CPT-11 and NPC (from stock solu-
tions containing 1.00 and 1.77 mg/ml in DMSO, diluted in a
mixture of methanol-0.01 M hydrochloric acid) were then added
to 450 ml of plasma to yield the desired final concentrations
(;0.2 to 200 mM), followed by slight agitation by vortex
mixing. To determine the reaction velocity (i.e., V expressed in
nM/h/l of plasma), sample aliquots were taken at a fixed time
interval of 24 h, which was determined in preliminary experi-
ments to be sufficiently long to achieve steady-state (not
shown), and analyzed for the presence of total SN-38 as de-
scribed above for plasma samples. The Michaelis-Menten ki-
netics of the maximum process rate (i.e., Vmax) and the drug
concentration associated with 0.5 3 Vmax (i.e., Km) were deter-
mined by a nonlinear regression analysis implemented on the
Number Cruncher Statistical System software package (version
5.X; Jerry Hintze, East Kaysville, UT, 1992).
Drug Transport by Caco-2 Cells. The human colon
adenocarcinoma cell line Caco-2 (American Type Culture Col-
lection, Rockville, MD) was grown as monolayers in DMEM
containing 10% heat-inactivated fetal bovine serum, 100 mg/ml
penicillin and streptomycin, and 2 mM freshly added L-gluta-
mine (all from Life Technologies, Inc., Breda, the Netherlands)
according to procedures recommended by the American Type
Culture Collection. Cells were grown at 37°C in a humidified
atmosphere in 5% CO2/95% air as stock cultures in 75-cm3
flasks and split at ;80% confluency using trypsin-EDTA.
Caco-2 cells were then seeded at a density of 2.5 3 104
cells/insert in Transwell 12-well plates containing 1-cm2 per-
meable polycarbonate inserts with a 0.4-mm pore size (Costar
Corp., Cambridge, MA). The Caco-2 cells were maintained to
monolayer growth by medium change every 3 days, until use in
transport experiments at 28 days after seeding. The apical side
of the cell layer (insert) contained 0.5 ml, whereas the basolat-
eral side (well) contained 1.5 ml. Transport studies were initi-
ated with CPT-11, SN-38, and SN-38G [all dissolved in a
mixture of methanol-0.01 M hydrochloric acid (1:1, v/v) and
diluted further in medium at final concentrations of 1.7 and 17
mM (CPT-11), 2.5 and 25 mM (SN-38), and 1.5 mM (SN-38G),
respectively], added to either the apical or basolateral side. The
final concentration of methanol in the dosing medium was
always ,1%. At the end of the experiment (1, 2, 6, or 24 h
continuous exposure times), the entire apical and basolateral
side solutions were collected separately in 1.5-ml polypropylene
tubes (Eppendorf, Hamburg, Germany) and then centrifuged for
5 min at 15,000 rpm (4°C) to remove residual particulate matter.
The supernatants were transferred to clean tubes and immedi-
ately stored at 280°C until analysis by HPLC as described (20).
Mean transport fractions were calculated as the fraction of the
total drug transported after exposure.
The b-glucuronidase content in the Caco-2 cells was meas-
ured using the phenolphthalein assay as described above for
feces samples (detection limit, 0.3 mg/h/mg of protein), and total
protein levels with the Coomassie-brilliant blue G-250 assay
(26).
RESULTS
Patient Characteristics and Toxicity. A total of 14 pa-
tients (4 females and 10 males) with various solid tumors was
studied, with a median performance status of 0 (range, 0–1).
The median age was 53 years (range, 37–71 years), and all
patients had normal hematopoietic and liver functions at the
time of the study; the median clinical chemistry values for all 14
patients included a total bilirubin level of 9 mM (range, 4–12
mM); a serum creatinine level of 103 mM (range, 72–132 mM);
ASAT and ALAT levels of 34 units/l (range, 17–185 units/l) and
22 units/l (range, 6–225 units/l), respectively; a total protein
concentration of 79 g/dl (range, 69–87); and a serum albumin
level of 45 g/dl (range, 38–51 g/dl). All 14 patients were
assessable for complete pharmacokinetics of CPT-11 and me-
tabolites. Overall, the treatment was very well tolerated, with
neutropenia being the main hematological toxicity, although
neutropenia graded $2 (on a 4-point scale according to National
Cancer Institute Common Toxicity Criteria version 2.0) was
encountered in only three patients (20%). Gastrointestinal tox-
icity was most prominent among nonhematological side effects,
with diarrhea graded $2 occurring in eight patients (53%) and
graded $3 in only 1 patient. One patient developed severe liver
dysfunction immediately after CPT-11 administration, with total
bilirubin levels rising to levels .250 mM within 200 h and
ASAT graded 3. This patient died eventually 9 days after
CPT-11 administration after experiencing grade 4 leukocytope-
nia, grade 4 neutropenia, and grade 4 diarrhea. Autopsy revealed
an obstructed biliary tree by pigment stones.
Pharmacokinetics. The plasma concentration-time pro-
files of SN-38 after CPT-11 treatment were very similar for all
patients studied (displayed in Fig. 1). In line with previous
findings (18, 22), plasma concentrations gradually increased to
reach peak levels within 1.5–3 h after start of the i.v. adminis-
tration and slowly began to decline thereafter. SN-38 concen-
trations still remained detectable at 500 h after drug adminis-
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tration [lower limit of quantitation of the HPLC assay, ;13 pM
(21)]. As a result, values for AUC0-inf and T1/2 were significantly
higher as compared with estimates based on standard sampling
time periods (Table 1). SN-38G was the principal metabolite of
CPT-11 (detected in plasma of most patients), with an estimated
T1/2 slightly decreased as compared with unconjugated SN-38.
The time profile of the molar concentration ratios of SN-38G
and SN-38 was also relatively consistent between patients (Fig.
2), showing peak values at ;6 h and a gradual decrease toward
the end of the sampling time period. Data obtained from the
patient with liver dysfunction and biliary obstruction showed
aberrant pharmacokinetic profiles (Fig. 3), with substantially
increased plasma concentrations of both SN-38G and SN-38.
In Vitro Studies. Because SN-38G is susceptible to the
effects of bacterial b-glucuronidases after hepatobiliary secre-
tion (18, 19), pretherapy values of fecal b-glucuronidase activity
were evaluated to gain insight into potential enterohepatic re-
circulation mechanisms involved in the prolonged circulation
times of SN-38. Individual levels of enzyme activity were found
to vary enormously between patients (range, 0.56–44.6 mg/
h/mg of feces) and were not related to any of the SN-38 kinetic
parameters (r 5 0.09; P 5 0.26), suggesting that interindividual
variation in this enzyme is unimportant in explaining SN-38
pharmacokinetic variability.
The potential of oxidative metabolites of CPT-11 taking
part in the overall production of SN-38 was evaluated in exper-
iments in freshly prepared human plasma at fixed concentrations
of NPC and CPT-11 (17). The formation of SN-38 from NPC
and CPT-11 by serum CE is shown in Fig. 4. For NPC, the mean
values of Km and Vmax obtained using the Michaelis-Menten
equation were 74 mM and 76 pmol/h/ml plasma, respectively,
which is within the same range as described for this conversion
previously in an experimental setting using human liver micro-
somes or purified hepatic CE (17). We also confirmed the
possibility of CPT-11 transformation to SN-38 in human plasma
with Km and Vmax values of 126 mM and 52 pmol/h/ml plasma,
respectively, which agree very well with data of a previous
study (27).
We have also studied the transepithelial flux of CPT-11,
SN-38, and SN-38-G using the human colonic cell line Caco-2,
a well-established model of human intestinal absorption (28–
30), to further define the potential role of enterohepatic circu-
lation in the kinetic profile of SN-38. The total transport fraction
was clearly time dependent because of increased transport rates
of the carboxylate forms of both compounds. CPT-11 and
SN-38 were found to be transported to the apical side in a
concentration-dependent manner with the 24-h exposure times,
with transport fraction values of 0.404 and 0.405 at low con-
centrations and 0.269 and 0.399 at the highest concentrations
tested, respectively. The flux from the basolateral to the apical
side was substantially greater (4–9-fold) than that from the
apical to the basolateral side. Interestingly, SN-38G could not be
transported to the basolateral side after exposure at the apical
side at the tested concentration. In addition, SN-38 could not be
detected after exposure to SN-38G in either compartment, con-
sistent with undetectable levels of b-glucuronidase in the
Caco-2 cells (not shown).
DISCUSSION
By prospectively measuring concentrations of CPT-11 and
its metabolites in plasma of cancer patients over an extended
sampling time period of 500 h, we demonstrated in the present
work that the terminal disposition half-life and AUC of the
active metabolite SN-38 are ;2-fold increased as compared
with estimates reported in earlier studies (18, 22). In addition,
we found that the SN-38-G:SN-38 plasma concentration ratio
decreases in time from ;7 (at 50 h) to ;1 (at 500 h). These data
not only emphasize the need to apply appropriate kinetic models
with sufficient sampling time points for the accurate estimation
of complete concentration-time profiles but may also have direct
significant clinical relevance in view of the fact that relation-
ships between drug exposure and effect (i.e., toxicity and effi-
cacy) are still poorly defined.
Several possible explanations can account for the increase
in disposition half-life of SN-38 and the time-varying SN-38G:
SN-38 concentration ratios after i.v. administration of CPT-11.
Previously, biliary secretion of CPT-11, SN-38, and SN-38G
has been described and quantitated in a rat model, whereas
intestinal reabsorption of biliary secreted radioactivity in that
same study already suggested recirculation of at least some of
the compounds (31). This, in combination with numerous clin-
ical data, has led to the proposed enterohepatic recirculation of
CPT-11 and its metabolites. It has been suggested in clinical
studies that the enterohepatic recirculation is so prominent that
its effects can be measured in the systemic circulation by a short
rise of concentration of SN-38 at ;8 h after i.v. administration
of CPT-11 (23). As described in earlier reports (18, 32) and
again in this study, we could not confirm a consistent rise in the
SN-38 plasma concentration shortly after systemic drug expo-
sure. Direct proof of a recirculation process of any of the
compounds has, to our knowledge, not yet been published. For
this reason, we investigated the intestinal absorption and
transepithelial flux of CPT-11, SN-38, and SN-38-G in vitro in
Caco-2 cell monolayers, an established model of human intes-
tinal drug absorption resembling the small bowel. In these in
vitro experiments, we found a time and concentration-dependent
Fig. 1 Plasma concentration-time profiles of SN-38 in 14 patients
treated with a 90-min i.v. infusion of CPT-11 at a dose level of 350
mg/m2. Inset, concentration-time data up to 10 h after start of drug
infusion.
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transport fraction for both CPT-11 and SN-38. Although the
transport fractions from basolateral to apical were higher as
compared with that from apical to basolateral, it is still possible
that in vivo transport from the intestinal lumen to the circulation
of CPT-11 and SN-38 is of clinical relevance, especially when
intraluminal concentration of either one of the compounds is
relatively high. SN-38G on the other hand could not be trans-
ported from the apical to basolateral side, consistent with its
increased aqueous solubility resulting from the highly polar
nature of the glucuronic acid group. In addition, the difference
in absorption pattern between SN-38 and SN-38G is in accord-
ance with the decreasing SN-38G:SN-38 ratio in time. Further-
more, we could not detect SN-38 after exposure of SN-38G in
any compartment of this model, consistent with the undetectable
levels of b-glucuronidase activity in the Caco-2 cells. There was
also no metabolism of CPT-11 in the Caco-2 cells, despite the
fact that cytochrome P-450 3A4, the major isoform in the human
intestine (33, 34), has been indicated to be present at low levels
in the Caco-2 cell line (35). To further examine the potential
contribution of cytochrome P-450 3A4, if any, to the transport
of CPT-11 using the Caco-2 cell system, experiments using cells
with increased expression of this isozyme induced with addition
of 1a,25-dihydroxyvitamin D3 (36) to the growth medium are
currently under investigation.
Because we found a concentration-dependent uptake of
SN-38 in the above-described model, high fecal SN-38 concen-
trations can be of clinical significance, in a sense that a potential
recycling of SN-38 reduces the effective clearance and may add
a distributional compartment by way of the enteric circuit. Many
glucuronides are susceptible to the effects of enterohepatic re-
circulation after hydrolysis through the action of bacterial and
Table 1 Summary of plasma pharmacokineticsa
CPT-11 SN-38 SN-38G
Cmaxb (mM) 7.53 6 2.20 0.168 6 0.115 0.639 6 0.258
AUC0–56 (mMzh) 41.7 6 13.9 1.12 6 0.570 11.0 6 9.26
AUC0–inf (mMzh) NDc 1.99 6 0.790 26.9 6 18.2
T1/2, 0–56 (h) 13.9 6 3.20 29.4 6 18.6 26.6 6 9.23
T1/2, 0–inf (h) NDc 47.0 6 7.90 39.2 6 24.3
CL (l/h/m2) 15.6 6 4.32
Vss (l/m2) 147 6 55.5
MRT (h) 10.4 6 2.89
REC (AUCSN-38:AUCCPT–11) 0.020 6 0.011 (range, 0.008–0.045)
REG (AUCSN–38G:AUCSN–38) 10.4 6 8.20 (range, 2.10–28.0)
BI [AUCCPT–11 3 (AUCSN–38:AUCSN–38G)] 2015 6 1359 (range, 439–5160)
a Data were obtained from 14 patients treated with a 1.5-h i.v. infusion of CPT-11 at a dose level of 350 mg/m2. Data are expressed as mean
values 6 SD.
b Cmax, peak plasma concentration; AUC, area under the plasma concentration-time curve; T1/2, half-life of the terminal disposition phase; CL,
total plasma clearance; Vss, volume of distribution at steady-state; MRT, mean residence time; REC, relative extent of conversion of CPT-11 into
SN-38; REG, relative extent of glucuronidation of SN-38 into SN-38G; BI, biliary index.
c CPT-11 could not be detected in plasma samples obtained at 196, 360 and 504 h after the end of infusion with the applied HPLC assay (lower
limit of quantitation, ;3.4 nM; Ref. 20).
Fig. 2 Concentration ratios of SN-38G and nonglucuronidated SN-38
(SN-38G:SN-38) as a function of time after CPT-11 infusion. Data were
obtained from 14 patients treated with a 90-min i.v. infusion of CPT-11
at a dose level of 350 mg/m2 and are displayed as mean values (F) 6
SD (bars). Inset, concentration ratio time data up to 30 h after start of
infusion.
Fig. 3 Plasma concentration time profiles of CPT-11 (F), SN-38G (E),
SN-38 () (all left y-axis) and total bilirubin (3, dotted line; right
y-axis) in a single patient with progressively impaired liver function
treated with a 90-min i.v. infusion of CPT-11 at a dose level of 350
mg/m2.
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enteric b-glucuronidases (37). Indeed, conversion of SN-38G to
SN-38 by bacterial intestinal b-glucuronidase has been shown to
occur in animal models (38) as well as in humans (18). In
addition, high intraluminal concentrations of SN-38 in combi-
nation with prolonged retention and subsequent structural and
functional injuries to the intestinal tract is considered to be one
of the mechanisms underlying the late-onset form of intestinal
toxicity encountered in patients treated with CPT-11 (39). To
assess the importance of SN-38G deconjugation with respect to
potential SN-38 recycling, we therefore also evaluated the levels
of b-glucuronidase activity in fecal pretreatment specimens of
individual patients. Interpatient enzyme activity varied up to a
100-fold and did not correlate with any of the plasma pharma-
cokinetic parameters of SN-38. Overall, this finding shows very
clearly that interindividual variation in this enzyme is unimpor-
tant in explaining SN-38 pharmacokinetic variability. This is
also consistent with our recent observation that modulation of
fecal b-glucuronidase activity by neomycin coadministration
has no significant influence on systemic (plasma) concentrations
of SN-38 (40). A potential approach for reducing CPT-11-
induced intestinal toxicity may therefore be to reduce bacterial
b-glucuronidase-mediated deconjugation of SN-38G to limit
local accumulation of SN-38 and subsequent mucosal destruc-
tion. A clinical trial to evaluate the toxicological consequences
of pretreatment with neomycin before the administration of
CPT-11 is in progress.4 The paradox between the concentration-
dependent absorption process of SN-38 in the Caco-2 cells and
the lack of relationship of fecal b-glucuronidase activity with
SN-38 pharmacokinetics is presumably caused by the lack of
enzyme activity in the luminal contents of the entire small
intestine, where reabsorption of drug is most likely to occur
(39).
Another possibility that could lead to prolongation of the
terminal disposition phase of SN-38 is its continuous formation
out of the oxidative metabolites of CPT-11. In an in vitro model,
conversion of APC to SN-38 by rabbit liver CE has been
described (41). However, rabbit liver CE, although very similar
to human liver CE with respect to amino acid sequence, is
;100-fold more efficient in activating APC then the human
enzyme in vitro (42). Indeed, in vitro conversion of APC to
SN-38 by human CE or human liver microsomes could not be
demonstrated (16), suggesting that APC is not a prodrug of
SN-38 in humans. NPC, on the other hand, could be metabolized
into SN-38 in vitro by human liver microsomes and human liver
CE to SN-38 after enzymatic cleavage of the 4-N-(1-piper-
idino)-1-amino group at C10 (17). We have reported recently
that peak plasma concentrations and AUC values of NPC are
very low after CPT-11 administration (32), which could point to
rapid and virtually complete conversion of this compound to
SN-38 in the systemic circulation. To test this possibility, we
evaluated the in vitro production of SN-38 from NPC and
CPT-11 in freshly prepared human plasma and found substantial
formation from both compounds. These data appear to indicate
that this metabolic pathway is underestimated in relationship to
what extent it adds to the total amount of SN-38 formed.
Although this route could clearly contribute to the prolonged
disposition phase of SN-38 and may be an important determi-
nant of the substantial interpatient variability in CPT-11 phar-
macokinetics observed here and elsewhere (32), the overall
quantitative aspects of this source of SN-38 remain unknown.
Another potential contributing factor to the prolonged cir-
culation time of SN-38 may come from competitive binding of
SN-38 and bilirubin to UDP glucuronosyltransferases (43).
Thus, in the lower concentration regions of SN-38, competitive
binding with bilirubin may inhibit glucuronidation and prolong
circulation times of the active metabolite. Although we do not
have direct proof for this mechanism in the clinical situation, it
is known that even minor liver enzyme disturbances and/or
slight hyperbilirubinemia can give significant rise in both he-
matological and intestinal toxicity (44–46). In patients with
(slightly) elevated bilirubin levels, competitive binding will
influence the early plasma SN-38 concentration only to a minor
extent but will give a disproportional prolongation of the termi-
nal disposition phase of SN-38 and is thus likely to affect
SN-38G:SN-38 concentration ratios. The importance of this
competitive interaction between SN-38 and bilirubin is further
underscored by our observations made in a single patient who
developed very severe toxicity. This patient developed liver
failure during treatment with CPT-11 accompanied with a dra-
matic rise in serum bilirubin concentrations. Compared with
4 D. F. S. Kehrer and A. Sparreboom, unpublished data.
Fig. 4 Kinetics of the biotransformation of SN-38 (V, velocity) from
CPT-11 (F, solid line) and NPC (E, dotted line) by human plasma as a
function of the substrate (S) concentration (A), and the same data in a
Michaelis-Menten plot [V 5 Vmax 3 [S]/([S] 1 Km)] (B).
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other patients, this patient experienced at least a 10-fold increase
in the SN-38 plasma concentrations, which is in accordance with
this hypothesis and consistent with other published data indi-
cating substantial increases in systemic exposure to CPT-11 and
SN-38 in patients with liver dysfunction (45).
In addition to the processes mentioned, a variety of other
factors may influence SN-38 pharmacokinetics, including bind-
ing of the compound to plasma proteins [principally human
serum albumin and gamma globulin (18)]. It has been well
established that for drugs with very high protein binding [e.g.,
SN-38, which is 94–96% bound (47)], prolonged sampling may
demonstrate a relatively slow redistribution of drug into plasma
and thus prolong the apparent half-life. For drugs undergoing
enterohepatic recirculation (e.g., SN-38), the times that patients
ingest food may also impact upon plasma drug concentrations.
However, although the times that the patients under study took
any food were not noted and its potential impact on kinetics
were not investigated here, a previous clinical study with the
related compound topotecan has shown that food intake does not
affect the extent of drug absorption (48).
In conclusion, we have shown by applying an extended
sampling time period of 500 h that until now the circulation time
of SN-38 in cancer patients treated with CPT-11 has been
greatly underestimated. Because of the poorly defined relation-
ships between pharmacokinetic parameters and pharmacody-
namic outcome of CPT-11 treatment, the presently observed
prolonged terminal disposition phase of SN-38 should be taken
into consideration in future studies attempting to identify kinetic
correlates that would assist in prediction of both hematological
and intestinal toxicity. Further investigation to reveal the clinical
importance of our findings is clearly warranted.
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